Nikhil Mayor1, Niranjan J Sathianathen1, James Buteau2, Samantha Koschel1, Marta Antón Juanilla1, Jada Kapoor1, Arun Azad3,4, Michael S Hofman2,4, Declan G Murphy1,4. 1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 2. Molecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Abstract
OBJECTIVES: To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. METHODS: Narrative review focussing on PSMA as a target for RLT, and data using RESULTS: RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate-resistant prostate cancer (mCRPC). To date, most evidence exists regarding small-molecule PSMA inhibitors bound to beta-emitting radioisotopes such as 177Lu (Lu-PSMA). Prospective phase II data supports the safety and efficacy of Lu-PSMA in men with heavily pre-treated progressive mCRPC, and several late-phase randomised trials of Lu-PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states. CONCLUSIONS: PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
OBJECTIVES: To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer. METHODS: Narrative review focussing on PSMA as a target for RLT, and data using RESULTS: RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate-resistant prostate cancer (mCRPC). To date, most evidence exists regarding small-molecule PSMA inhibitors bound to beta-emitting radioisotopes such as 177Lu (Lu-PSMA). Prospective phase II data supports the safety and efficacy of Lu-PSMA in men with heavily pre-treated progressive mCRPC, and several late-phase randomised trials of Lu-PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states. CONCLUSIONS:PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
Authors: Finn Edler von Eyben; Glenn Bauman; Rie von Eyben; Kambiz Rahbar; Cigdem Soydal; Alexander R Haug; Irene Virgolini; Harshad Kulkarni; Richard Baum; Giovanni Paganelli Journal: Int J Mol Sci Date: 2020-11-28 Impact factor: 5.923
Authors: Stephen Mackay; Naomi L Hitefield; Ian O Oduor; Autumn B Roberts; Tanya C Burch; Raymond S Lance; Tina D Cunningham; Dean A Troyer; Oliver J Semmes; Julius O Nyalwidhe Journal: ACS Omega Date: 2022-08-18